Methylergonovine Maleate Injection, USP (0.2 mg/ml)
... Methylergonovine maleate acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I ...
... Methylergonovine maleate acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I ...
P. aeruginosa
... Penicillin G® is a drug of choice for infections caused by streptococci, meningococci, enterococci, penicillinsusceptible pneumococci, non-β-lactamase-producing staphylococci, T. pallidum and many other spirochetes, clostridium species, actinomyces, and other Grampositive rods and non-β-lactamase- ...
... Penicillin G® is a drug of choice for infections caused by streptococci, meningococci, enterococci, penicillinsusceptible pneumococci, non-β-lactamase-producing staphylococci, T. pallidum and many other spirochetes, clostridium species, actinomyces, and other Grampositive rods and non-β-lactamase- ...
The Development of New Therapeutics for Alzheimerʼns Disease
... commencing with protein misfolding and ultimately culminating in behavioral symptoms. If a therapeutic target is “high” in this cascade (e.g., protein misfolding), the resulting agent may be disease-modifying or even curative; if a therapeutic target is “low” is this cascade (e.g., neurotransmitter ...
... commencing with protein misfolding and ultimately culminating in behavioral symptoms. If a therapeutic target is “high” in this cascade (e.g., protein misfolding), the resulting agent may be disease-modifying or even curative; if a therapeutic target is “low” is this cascade (e.g., neurotransmitter ...
Provisional PDF - Thrombosis Journal
... between treatment groups across renal function categories (pinteraction = 0.72). Major bleeding in rivaroxaban recipients occurred in 0.8%, 1.4%, 0.9%, and 0%, respectively (ptrend = 0.50). Respective rates in enoxaparin/VKA recipients were 1.0%, 3.0%, 3.9%, and 9.1% (ptrend < 0.001). Rivaroxaban–en ...
... between treatment groups across renal function categories (pinteraction = 0.72). Major bleeding in rivaroxaban recipients occurred in 0.8%, 1.4%, 0.9%, and 0%, respectively (ptrend = 0.50). Respective rates in enoxaparin/VKA recipients were 1.0%, 3.0%, 3.9%, and 9.1% (ptrend < 0.001). Rivaroxaban–en ...
octaplex - Octapharma Canada
... vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. Human prothrombin complex concentrates (PCCs) contain the coagulation factors II, VII, IX and X. In principle, they are indicated for prophylaxis and treatment of acquired def ...
... vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. Human prothrombin complex concentrates (PCCs) contain the coagulation factors II, VII, IX and X. In principle, they are indicated for prophylaxis and treatment of acquired def ...
What is the risk of gastrointestinal bleeding associated with selective
... taking multiple drugs that could cause bleeding, it has been recommended that informed medical advice is sought before starting regular use of non-prescription drugs, such as ibuprofen. Also, paracetamol should be considered as an alternative to an NSAID in patients who are taking SSRIs ...
... taking multiple drugs that could cause bleeding, it has been recommended that informed medical advice is sought before starting regular use of non-prescription drugs, such as ibuprofen. Also, paracetamol should be considered as an alternative to an NSAID in patients who are taking SSRIs ...
Product Monograph
... Agranulocytosis and bone marrow depression have been caused by ACE inhibitors. The risk of neutropenia appears to be dose- and type-related and is dependent on the patient’s clinical status. These reactions are more frequent in patients with renal impairment, especially those with a collagen vascula ...
... Agranulocytosis and bone marrow depression have been caused by ACE inhibitors. The risk of neutropenia appears to be dose- and type-related and is dependent on the patient’s clinical status. These reactions are more frequent in patients with renal impairment, especially those with a collagen vascula ...
Chemotherapy regimen: Dose adjusted EPOCH
... CHOP One study evaluated the clinical impact of co-administration of combination antiretroviral therapy (cART) with CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 [max 2 mg], prednisone 100 mg/m2) in the context of treatment for non-Hodgkin’s lymphoma. In comparison wi ...
... CHOP One study evaluated the clinical impact of co-administration of combination antiretroviral therapy (cART) with CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 [max 2 mg], prednisone 100 mg/m2) in the context of treatment for non-Hodgkin’s lymphoma. In comparison wi ...
acute pain relief in children with renal impairment
... Special considerations must be given to patients with renal impairment to minimize direct analgesicinduced renal-related complications and other drug-accumulation-related complications due to reduced renal clearance. Impaired renal function may lead not only to an accumulation of ingested components ...
... Special considerations must be given to patients with renal impairment to minimize direct analgesicinduced renal-related complications and other drug-accumulation-related complications due to reduced renal clearance. Impaired renal function may lead not only to an accumulation of ingested components ...
Warfarin Management - Adult
... 12.1 A baseline INR must be resulted in the EMR prior to verification of the first dose of warfarin (Class IIb, Level C) 12.2 A current INR must be resulted in the EMR prior to verification of the warfarin dose adjustment (Class IIb, Level C) 12.3 Obtain daily INR for patients with daily warfarin do ...
... 12.1 A baseline INR must be resulted in the EMR prior to verification of the first dose of warfarin (Class IIb, Level C) 12.2 A current INR must be resulted in the EMR prior to verification of the warfarin dose adjustment (Class IIb, Level C) 12.3 Obtain daily INR for patients with daily warfarin do ...
Vasotec® IV
... therapy which may include subcutaneous adrenaline solution 1:1000 (0.3 mL to 0.5 mL) and/or measures to ensure a patent airway should be administered promptly when indicated. If angioedema occurs, Vasotec IV should be discontinued promptly and appropriate monitoring should be instituted to ensure co ...
... therapy which may include subcutaneous adrenaline solution 1:1000 (0.3 mL to 0.5 mL) and/or measures to ensure a patent airway should be administered promptly when indicated. If angioedema occurs, Vasotec IV should be discontinued promptly and appropriate monitoring should be instituted to ensure co ...
beta lactam antibiotics and other cell wall synthesis
... 3. impaired penetration of drug to target PBPs 4. presence of an efflux pump Kinetics: - absorption vary with the preparation depending ...
... 3. impaired penetration of drug to target PBPs 4. presence of an efflux pump Kinetics: - absorption vary with the preparation depending ...
Opioids for Pain in the Elderly
... reduced metabolism due to genetic factors or if on 2D6 inhibitors*.26 codeine alone is a weak analgesic with very limited effectiveness. 15 Combination with acetaminophen increases analgesic efficacy; however limit acetaminophen to ≤4g/day (ideally ≤3.2g/day) to reduce hepatic risk2 . The caff ...
... reduced metabolism due to genetic factors or if on 2D6 inhibitors*.26 codeine alone is a weak analgesic with very limited effectiveness. 15 Combination with acetaminophen increases analgesic efficacy; however limit acetaminophen to ≤4g/day (ideally ≤3.2g/day) to reduce hepatic risk2 . The caff ...
Vol 19 #3 - Vancouver Acute Pharmaceutical Sciences
... 1. Azacitidine 100 mg injection (Vidaza) • Antineoplastic agent used at VA to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) • Restricted to indications as outlined in the BCCA Benefit Drug List and patients who are registered with BCCA 2. Bicalutamide 50 mg tablets (Casodex ...
... 1. Azacitidine 100 mg injection (Vidaza) • Antineoplastic agent used at VA to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) • Restricted to indications as outlined in the BCCA Benefit Drug List and patients who are registered with BCCA 2. Bicalutamide 50 mg tablets (Casodex ...
Chemotherapy regimen: Hyper CVAD
... cyclophosphamide doses per cycle are lower though doxorubicin dose is the same. They did not observe any difference in response rates, dose intensity or number of cycles of chemotherapy when CHOP was co-administered in 24 patients with a PI based cART (saquinavir, indinavir or ritonavir) in comparis ...
... cyclophosphamide doses per cycle are lower though doxorubicin dose is the same. They did not observe any difference in response rates, dose intensity or number of cycles of chemotherapy when CHOP was co-administered in 24 patients with a PI based cART (saquinavir, indinavir or ritonavir) in comparis ...
daniels-broiler-3-2
... weight loss and a concomitant decrease in food consumption during the first week of dosing. No teratogenic or embryo-fetal effects were observed at doses equivalent to up to 22.5 mg/kg per day rolapitant free base (approximately 1.2 times the recommended human dose on a body surface area basis). In ...
... weight loss and a concomitant decrease in food consumption during the first week of dosing. No teratogenic or embryo-fetal effects were observed at doses equivalent to up to 22.5 mg/kg per day rolapitant free base (approximately 1.2 times the recommended human dose on a body surface area basis). In ...
Emory`s CNE Sept 13 WORD
... weight loss and a concomitant decrease in food consumption during the first week of dosing. No teratogenic or embryo-fetal effects were observed at doses equivalent to up to 22.5 mg/kg per day rolapitant free base (approximately 1.2 times the recommended human dose on a body surface area basis). In ...
... weight loss and a concomitant decrease in food consumption during the first week of dosing. No teratogenic or embryo-fetal effects were observed at doses equivalent to up to 22.5 mg/kg per day rolapitant free base (approximately 1.2 times the recommended human dose on a body surface area basis). In ...
Warfarin Use Has no Effect on Blood Pressure of Patients With
... Introduction: Warfarin causes arterial calcification, arterial stiffness and systolic hypertension in animals. Early evidence in humans indicates that a similar effect may occur in patients with diabetes mellitus (DM) and/or hypertension. Objective: To evaluate whether warfarin use causes elevated b ...
... Introduction: Warfarin causes arterial calcification, arterial stiffness and systolic hypertension in animals. Early evidence in humans indicates that a similar effect may occur in patients with diabetes mellitus (DM) and/or hypertension. Objective: To evaluate whether warfarin use causes elevated b ...
Prescribing Information
... days to 2 years. Six patients had thrombocytopenia, three of which had platelet counts 30,000/microL or lower. In 4 patients with thrombocytopenia, platelet counts gradually returned to normal (duration up to 47 days) without change in ORFADIN dose. No patients developed infections or bleeding as a ...
... days to 2 years. Six patients had thrombocytopenia, three of which had platelet counts 30,000/microL or lower. In 4 patients with thrombocytopenia, platelet counts gradually returned to normal (duration up to 47 days) without change in ORFADIN dose. No patients developed infections or bleeding as a ...
Drug Effecting Platelet Function
... decreasing one of the signals for intracellular calcium release. In case-control studies they were associated with up to a 10% increase in the rate of gastrointestinal tract (GIT) bleeding, with the risk being highest for octogenarians ...
... decreasing one of the signals for intracellular calcium release. In case-control studies they were associated with up to a 10% increase in the rate of gastrointestinal tract (GIT) bleeding, with the risk being highest for octogenarians ...
20110503_Manuscript - international journal of advances in
... about 0.6 h. After oral administration plasma apixaban exposure was low, with an absolute oral bioavailability of 3%. After IV administration about 24.8% and 62.4% of apixaban was excreted in the urine and feces respectively in 48 hrs in rabbits. While after oral administration, about 1.8% and 54.3% ...
... about 0.6 h. After oral administration plasma apixaban exposure was low, with an absolute oral bioavailability of 3%. After IV administration about 24.8% and 62.4% of apixaban was excreted in the urine and feces respectively in 48 hrs in rabbits. While after oral administration, about 1.8% and 54.3% ...
Enhanced water solubility for enhanced oral drug delivery via the
... etexilate (Pradaxa; Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany), a direct thrombin inhibitor for stroke prevention, which has been available in Europe and many other countries since 2008. However, it was not until the October 2010 when dabigatran etexilate became the first oral alternative ...
... etexilate (Pradaxa; Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany), a direct thrombin inhibitor for stroke prevention, which has been available in Europe and many other countries since 2008. However, it was not until the October 2010 when dabigatran etexilate became the first oral alternative ...
Application of drugs based on release-active
... Reports in international press on adverse events associated with the drug use ...
... Reports in international press on adverse events associated with the drug use ...
Dr. Amani A. Noory Khartoum, Sudan
... impairment of work capacity No sedation or CNS effect Can be given to asthma, angina and PVD patients No renal and male sexual function impairment No adverse fetal effects and can be given in pregnancy Minimal effect on quality of life ...
... impairment of work capacity No sedation or CNS effect Can be given to asthma, angina and PVD patients No renal and male sexual function impairment No adverse fetal effects and can be given in pregnancy Minimal effect on quality of life ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.